Today's Date: February 3, 2023
American Marketing Association San Diego Launches New Sandie Awards and Opens Call for Entries   •   Introduction of Diagnostic and Supplemental Imaging Legislation Would Benefit Thousands of Marylanders   •   Experiences of Black Women With Breast Cancer Highlight Need for Better Care, Improved Outcomes   •   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Veru Inc. (VERU)   •   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NeoGenomics, Inc. (NE   •   Founder’s Day: Reflecting on a legacy of Black history at St. Jude Children’s Research Hospital   •   Hyundai and TEN Advertising Develop Their First Asian American Campaign "My Love, My Son-in-Law" for the Tucson SUV   •   Boston Celtics and Sun Life close out 9th annual Fit to Win youth program with Celtics forward Justin Jackson at trampoline park   •   Government of Canada to support clean air and local economic growth by powering federal operations in Alberta and Saskatchewan w   •   US Fertility founding partner Shady Grove Fertility (SGF) announces Egg Freezing for Surgical Residents Program in celebration o   •   TWO PUBLIC ALLIES ALUMNI JOIN THE NATIONAL BOARD OF DIRECTORS   •   General Dynamics Elects Richard Clarke to Board of Directors   •   Joaquin Sabina in USA   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Honda Motor Co., Ltd. with Losses of $100,000 to Contact t   •   Feinstein Institutes researcher discovers potential therapeutic target for lethal sepsis   •   Scottsdale Tesla Drivers Club and PS Academy Arizona Work Together on Tesla Cybertruck Build   •   Worldwide Shipments of Tablets and Chromebooks Declined Sharply in 2022, According to IDC Tracker   •   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Affirm Holdings, Inc.   •   Conemaugh Miners Medical Center and Conemaugh Meyersdale Medical Center Achieve Designation as Lifepoint Health National Quality   •   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Invivyd, Inc. f/k/
Bookmark and Share

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES , December 05 /Businesswire/ - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 20,625 shares of Puma common stock to three new non-executive employees.

The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award’s vesting commencement date, December 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.


STORY TAGS: Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, United States, North America, California, Share Issue,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News